Androgens and androgen receptors play essential roles in the development and progression of prostate cancer, a disease that claims roughly 28,000 lives annually. In addition to androgen binding, androgen receptor activity can be regulated via several post-translational modifications such as ubiquitination, acetylation, phosphorylation, methylation & SUMOylation. Of these modifications, phosphorylation has been the most extensively studied. Modification by phosphorylation can alter androgen receptor localization, protein stability and transcriptional activity, ultimately leading to changes in the biology of cancer cells and cancer progression. Understanding, role of phosphorylated androgen receptor species holds the key to identifying a potential therapeutic drug target for patients with prostate cancer and castrate resistant prostate cancer. Here, we present a brief review of recently discovered protein kinases phosphorylating AR, focusing on the functional role of phosphorylated androgen receptor species in prostate cancer and castrate resistant prostate cancer.

Keywords: LMTK2; MAPK; Lyn; Androgen Receptor; Castrate Resistant Prostate Cancer; Prostate Cancer; Kinases; Signaling

clinically these cancer appear ‘androgen independent’ the AR still seems to play a role in cancer cell growth. These findings suggested that AR signaling pathways are still intact in CRPC. Indeed, recent studies have argued that receptor-mediated endocytosis of androgens may contribute to an efficient uptake of hormone despite a low circulating androgen level \[12\]. Critical to understanding how prostate cancer cells can grow with an apparent lack of androgens is an understanding of the molecular mechanisms by which modulation of AR signaling cascades can occur. This review will focus on kinase-dependent modulation of AR signaling, and will outline how understanding of kinase pathways could lead to potential new therapies.

**Androgen and Androgen Receptor Signaling**

The prostate is a walnut-sized gland found between the bladder and the penis, where its main function is to secrete a fluid that nourishes and protects sperm. During ejaculation, the prostate squeezes this fluid into the urethra and is expelled along with sperm. Androgens and their receptors play an important role in the development and maintenance of the prostate gland. The main circulating androgen in males is testosterone, which enters prostate cells predominantly via free diffusion, but also via endocytosis with the help of megalin, a multi-ligand endocytic receptor (megalin may be particularly important in CRPC states) \[12\]. Upon entering prostatic stromal and basal cells, testosterone is reduced to dihydrotosterone (DHT) by the enzyme, 5-α reductase \[13\]. This conversion is necessary for complete prostate morphogenesis as evident by small or undetectable prostate glands in individuals lacking a functional 5-α reductase enzyme \[14\]. Androgens are also necessary for the initiation of prostate development. Thus, the prostate is absent in individuals with AR insensitivity due to mutations of AR, that alters androgen binding efficiency, as well as AR knockout mice and in testicular feminized mice (Tfm), which lack functional AR \[15\-18\]. Interestingly, although AR plays a key role in the normal differentiation and maintenance of the prostate, AR also plays an essential part in driving malignant development of prostate cancer. Following the development of the prostate gland, AR continues to play an important role in promoting the survival of its secretory epithelia, the primary cell type transformed in prostate adenocarcinoma \[19\]. In a normal healthy prostate, cell death occurs each day at a rate of ~1-2%, but this is equally matched by the rate of cell proliferation, which, as noted, is dependent upon AR activity \[20\, 21\]. So how does AR regulate cell proliferation? In the absence of androgens, AR is primarily present in an inactive state, bound to heat shock proteins (HSP-90, -70, -56) in the cell cytoplasm \[22\-24\]. AR is a nuclear receptor that, upon activation by androgens, traffics to the nucleus and mediates transcription of androgen-responsive genes. AR protein consists of three major functional domains: The N-terminal domain, a DNA-binding domain (DBD) and a Ligand-binding domain (LBD) (Figure 1). Binding of androgen to its ligand-binding pocket on AR, results in a conformational change in the receptor leading to homo-dimerization, exposure of Nuclear Localization Signals (NLS) and the formation of new interactions with AR-coactivators. These modifications facilitate nuclear translocation of AR following which it binds to androgen response elements (ARE), which can be found in the promoter and enhancer regions of androgen responsive genes, including those known to promote cell proliferation e.g. Prostate-Specific Antigen (PSA) & Vascular Endothelial Growth Factor (VEGF). The AR transcriptional complex is thus able to modulate gene expression of these target genes and regulate cell proliferation.

In addition to androgen binding several post-translational modifications including phosphorylation, SUMOylation, ubiquitination, methylation, and acetylation have also been discovered to regulate AR activity \[25\]. Off these modifications, phosphorylation has been the most extensively studied. Van Laar et al first reported phosphorylation of AR \[26, 27\] in 1990. A two-fold increase in phosphorylation was observed after 30 min incubation of LN1CaP, a androgen dependent prostate adenocarcinoma cells with 10nm R1881, a synthetic androgen analog. AR has
phospho-serine, -threonine and -tyrosine sites on each of its major domains. Phosphorylation at many of these sites can regulate cell growth, AR-transcriptional activity and its sensitivity to androgens. For example, phosphorylation of AR by CDK1 and CDK9 can regulate the transcriptional activity of AR by regulating AR expression or transactivation respectively. Lyn, CDK5 and Lyn have also been implicated in manipulating AR signaling pathways and support the progression of prostate cancer to advanced androgen-independent stages of prostate cancer.[30, 31]. Understanding, detailed molecular mechanisms and the role of the various phosphorylated AR species holds the key to identifying phosphorylation sites that could serve as a potential therapeutic drug targets for patients with prostate cancer and CRPC. In this article, we review a few of the recently discovered protein kinases regulating AR activity. Also, we also provide a list of several known kinases and their respective phosphorylation sites in AR (Table 1).

### Table 1. List of the known kinases phosphorylating AR and their respective phosphorylation sites in AR are indicated wherever possible. References are included. This table is not intended to be the comprehensive list, but rather to highlight a few well-studied kinases phosphorylating AR.

<table>
<thead>
<tr>
<th>Sr. No</th>
<th>Kinase</th>
<th>Experimentally Determined Site</th>
<th>Function</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>CDK1</td>
<td>S-81, S515</td>
<td>CDK1 could increase AR expression.[28,29]</td>
</tr>
<tr>
<td>2</td>
<td>Lyn</td>
<td>Unknown</td>
<td>Lyn may enhance the AR-transcriptional activity.[30]</td>
</tr>
<tr>
<td>3</td>
<td>LMTK2</td>
<td>Unknown</td>
<td>LMTK2 may negatively regulate the AR-transcriptional activity.[30]</td>
</tr>
<tr>
<td>4</td>
<td>MKK4/JNK</td>
<td>S-650</td>
<td>Stress Kinase could negatively regulate the AR-transcriptional activity.[38]</td>
</tr>
<tr>
<td>5</td>
<td>MKK6/p38</td>
<td>S-650</td>
<td>Stress Kinase may negatively regulate the AR-transcriptional activity.[38]</td>
</tr>
<tr>
<td>6</td>
<td>Akt</td>
<td>S-210, S-790</td>
<td>AKT may suppresses AR-induced apoptosis.[61]</td>
</tr>
<tr>
<td>7</td>
<td>Src</td>
<td>Y-534</td>
<td>Src could promote the AR-transcriptional activity.[62]</td>
</tr>
<tr>
<td>8</td>
<td>CDK5</td>
<td>S-81, S308</td>
<td>CDK5 could increase AR stabilization and transactivation.[63,64]</td>
</tr>
<tr>
<td>9</td>
<td>CDK9</td>
<td>S-81</td>
<td>CDK9 could promote the AR-transcriptional activity.[20]</td>
</tr>
<tr>
<td>10</td>
<td>IKK1/IKK2</td>
<td>Unknown</td>
<td>IKK1 could act as positive regulator of the AR activity, whereas, IKK2 could act as negative regulator.[65]</td>
</tr>
<tr>
<td>11</td>
<td>PIM-1</td>
<td>S-213</td>
<td>PIM-1 could act as a negative regulator of the AR-transcriptional activity.[66]</td>
</tr>
<tr>
<td>12</td>
<td>Aurora-A</td>
<td>T282 &amp; S293</td>
<td>Aurora-A may activate AR.[67]</td>
</tr>
<tr>
<td>14</td>
<td>CDK7</td>
<td>S515</td>
<td>TFIIH transcription factor via CDK7 may be required for AR transactivation.[69]</td>
</tr>
<tr>
<td>15</td>
<td>PKC</td>
<td>Unknown</td>
<td>PKC has been implicated as positive and negative regulator of AR-responsive PSA gene.[70,71]</td>
</tr>
<tr>
<td>16</td>
<td>PAK6</td>
<td>S578</td>
<td>PAK6 may promote ubiquitin-mediated AR degradation.[72]</td>
</tr>
<tr>
<td>17</td>
<td>Ack</td>
<td>Y267 &amp; Y363</td>
<td>Y267 phosphorylation may be critical for castration-resistant AR transactivation.[73]</td>
</tr>
<tr>
<td>18</td>
<td>Gsk3β</td>
<td>Y223</td>
<td>Gsk3β may inhibit AR-driven transcription.[76]</td>
</tr>
<tr>
<td>19</td>
<td>ZIP Kinase</td>
<td>Unknown</td>
<td>ZIP kinase may enhance the AR-mediated transactivation. ZIP kinase failed to phosphorylate AR in-vitro.[70]</td>
</tr>
</tbody>
</table>

**Stress Kinase Signaling**

The mitogen-activated (MAP) kinase signaling pathways are some of the most highly conserved pathways amongst eukaryotes.[32] Of the four identified MAP kinases, c-Jun N-terminal kinase (JNK) and p38 MAP kinase are together referred to as stress-activated MAP kinases. Stress kinases get activated in response to a variety of environmental stresses including osmotic and oxidative stresses, heat shock, UV-irradiation, protein synthesis inhibitors and DNA-damaging agents.[33-35] Upon activation, stress kinases phosphorylate and activate several transcriptional factors such as ATF2 and Elk-1, which in turn regulate gene expression in response to cellular stress.[36-38]. Importantly, stress kinases have not only been implicated in playing a role in tumor suppression but paradoxically, also in tumor formation and development. Since, stress kinases regulate several transcription factors, their role as tumor suppressors or activators may differ from one tumor microenvironment to another.

One of the roles of stress kinases in the prostate tumor milieu is to regulate AR signaling pathway (Figure 2). Gioeli et al. were first to show that the signaling from MAP kinase 4 & 6 (MKK4 & MKK6) could lead to JNK and/or P38 mediated phosphorylation of AR at serine-650.[38] The proximity of serine-650 to AR Nuclear Exit Signals (NES) suggested that such phosphorylation might regulate AR nuclear exit and a reduction in AR signaling. Supporting this hypothesis, nuclear-cytoplasmic shuttling assays demonstrated that stress kinases did indeed induce AR-S650 phosphorylation, which was required for AR nuclear exit. In contrast, inhibiting protein expression levels of MKK4 and MKK6 using siRNA in LNCaP cells resulted in a significant increase in AR transcriptional activity, as measured by PSA mRNA levels. Hence, in the context of AR signaling in prostate epithelia, stress kinase signaling appears to play a key role in tumor suppression. Further support for the role of stress-kinase signaling in tumor suppression comes from a
systematic study that shows up-regulation of M KK4 and M KK6 protein levels in pre-neoplastic and neoplastic human prostate tissue, presumably in an attempt to limit AR signaling and tumor progression [39].

Lyn tyrosine Kinase

Lyn tyrosine kinase, a member of the SRC family of tyrosine kinase (SFK) plays an important role in regulating several epithelial and hematopoietic cellular events including cell survival, proliferation, differentiation and cell migration [40]. Lyn kinase, which was originally discovered in the context of hematopoietic cells, is also expressed in the prostatic epithelia of normal individuals and patients with and prostate cancer [41]. Interestingly, Goldenberg et al. in 2004 first showed that while the average calculated area of the largest cross-section for the prostate gland in control (Lyn +/-) mice was 6.74 mm² +/- 0.34 mm², it was significantly reduced in Lyn-deficient mice (Lyn -/+) to 2.83 mm² +/- 0.44 mm². The study also observed diminution in the thickness of prostatic epithelia as well as in the complexity of the prostate ductal network in Lyn -/+ mice compared to Lyn +/+. Together, these findings suggested a role for Lyn kinase in the development and physiology of the prostate epithelium [41].

In an effort to elucidate the mechanisms underlying the role of Lyn tyrosine kinase in prostate cancer, Zardan et al. found that while there was no significant difference in Lyn expression between normal prostate and primary androgen sensitive prostate tumors, Lyn expression was two-fold higher in CRPC specimens when compared with primary prostate cancer specimens [30]. Furthermore, in-vitro studies of Lyn expression using prostate cancer cell lines, and in-vivo using CRPC xenograft mice models revealed that Lyn expression was up-regulated under androgen-deprivation conditions [30]. These findings suggest that Lyn expression in prostate cancer cells is regulated by androgen deprivation and is correlated with progression to the CRPC state. Moreover, overexpression of Lyn in androgen-deprived L N C A P cells resulted in a six-fold increase in AR signaling as measured by an AR-dependent luciferase reporter assay or quantitation of mRNA expression for PSA and the AR downstream gene FKBP51 [30]. Collectively, the data suggest that not only is Lyn expression correlated with progression to CRPC, but also that, Lyn is a potent inducer of AR signaling.
transcriptional activity, which is also associated with progression to the CRPC state.

Zardan et al. also suggested a mechanism through which Lyn might be regulating AR [30]. Their study found that in the absence of Lyn there was enhanced proteasome-mediated AR degradation. Treatment of Lyn knock down cells with the proteasome inhibitor MG-132 abrogated the AR protein degradation associated with loss of Lyn, and led to increased AR signaling. Thus an increase in Lyn expression, as seen in CRPC, could be expected to be associated with increased AR stability and hence increased AR signaling. Further investigation revealed that AR degradation associated with the loss of Lyn could be due the dissociation of AR from Hsp90, a molecular chaperone primarily responsible for stabilizing AR in its unbound state. The stability of AR might not be an issue in the presence of its ligand or AR activators, however in the androgen castrate condition, lack of ligand requires an increased stability of unbound AR and this may be achieved by increase in expression of Lyn, the precise event observed in CRPC tissues.

We now have a basic understanding of the role of Lyn kinase in prostate cancer. Apart from increasing the stability of ligand-unbound AR, it is possible that Lyn also supports AR transcriptional activity via phosphorylation events however this has yet to be investigated.

Protein Kinase A

Although more typically associated with acute, non-steroidal, signaling pathways, cAMP-dependent protein kinase (PKA) also modulates AR signaling pathways. Studies by Nazareth et al. showed that PKA activation can activate AR-dependent transcription in the absence of exogenous androgens; a finding abolished by the addition of PKA inhibitory peptide [42]. That the response to PKA activation was lost in the presence of the AR antagonists’ flutamide and bicalutamide indicated that AR was necessary to mediate the PKA effect. In addition, Sadar observed that treatment of LNCaP cells with the PKA activator forskolin, led to a dose- and time-dependent increase in PSA mRNA levels [43]. Again such responses were blocked by the AR-antagonist bicalutamide. Intriguingly, Blok and colleagues [44, 45] reported that rather than increasing AR phosphorylation, PKA activation, in fact, led to a decrease in AR phosphorylation, specifically on residues Ser 641 and 654. Although unusual, decreased protein phosphorylation upon PKA activation is not without precedent. For example, ribosomal protein S6 and the retinoblastoma gene product (Rb) are dephosphorylated following PKA activation [46,47]. The rapid nature of the PKA dependent AR dephosphorylation suggests the actions of an ancillary phosphatase. Indeed the actions of a few phosphatases are known to be regulated by PKA activation. For example, the nuclear protein phosphatase-1 (PP-1N) is activated by PKA induced phosphorylation of nuclear inhibitor of protein phosphatase-1 (NIPP-1) [48]. Dephosphorylation of AR may involve this phosphatase, or another similarly regulated phosphatase. A potential reconciliation of the PKA data suggests that dephosphorylated non-ligated AR may be transcriptionally active (i.e., ligand independent activation). The discrepancy between the data of Blok and Nazareth, may unfortunately also reflect a cellular model difference (CV1 versus LNCaP) and differences in reporter genes (adenoviral-mediated DNA transfer versus endogenous genes).

Lemur Tyrosine Kinase-2

Lemur Tyrosine Kinase-2 (LMTK2), also known as BREK, KPI2, LMR2, AATYK2 and PPP1R100 is a member of the membrane-associated protein tyrosine kinase family [49, 50]. Although being classified as a tyrosine kinase by gene alignment, LMTK2 was found to phosphorylate only serine or threonine residues on protein substrates [51]. Despite being discovered a decade ago, researchers have just started focusing on the physiological importance of LMTK2. Renewed interest in this kinase, primarily stems from several Genome-Wide Analysis Studies (GWAS) showing a significant (P<0.0001) association between a genetic variant of LMTK2 with an intron 9 SNP and susceptibility to prostate cancer [52-55]. Furthermore, a comparative study of LMTK2 mRNA levels in tissue from patients prostate cancer and Benign Prostatic Hyperplasia (BPH) revealed a markedly reduced level of LMTK2 in prostate cancer patients [53]. Recently, using immunohistochemistry we demonstrated that LMTK2 protein levels are also down-regulated in human prostate cancer tissue in comparison to adjacent non-cancerous tissue or tissue from patients with BPH [51]. Furthermore, we identified AR to be a binding partner of LMTK2 in prostate cancer epithelial cells. Interestingly, while LMTK2 interacts with AR primarily in the cytoplasm of cells deprived of androgens, such interactions were also found in the nucleus of cells grown in the presence of synthetic androgen, R1881 suggesting that LMTK2 interacts with AR in presence and absence of androgens. Furthermore, prostate cancer cells transfected with shRNA against LMTK2 (LMTK2-KD) showed significantly higher AR activity in the presence and absence of ligand, as measured by mRNA and protein levels of several AR-dependent genes and an AR-dependent luciferase assay. Collectively, these data suggests that LMTK2 negatively regulates AR-transcriptional activity in prostate epithelia, and loss of LMTK2, as occurs in prostate cancer, can lead to an increase in AR activity. One of the important findings from this study
was the role of LMTK2 in CRPC. FKBPs1, an AR-dependent gene, which is also a positive feedback regulator of AR expression, is expressed two-fold higher in CRPC compared to primary tumors [56, 57]. LMTK2-KD prostate cancer cells deprived of androgen had significantly higher levels of FKBPs1 in comparison to cells expressing normal levels of LMTK2. These results provide strong evidence of a role for LMTK2 in pathogenesis and progression of prostate cancer. In addition, cell viability data from the study argues for the strongest role of the decrease in LMTK2 in regards to androgen-independent growth in prostate cancer cells, androgen-dependent growth was also affected, although to a lesser degree.

Mechanisms though which LMTK2 might mediate its effect on AR are not yet known. In fact, very little is known in terms of signaling molecules upstream to LMTK2. Recently, Christopher Miller’s group showed that CDK5/p35 phosphorylates LMTK2 at serine-1418, enabling LMTK2 to phosphorylate protein phosphatase 1 (PP1C) at threonine-320 and inactivate the phosphatase[58]. PP1C is an important phosphatase regulating a diverse array of function, including AR. PP1C can negatively regulate the AR-transcriptional activity by dephosphorylating AR at serine-650 [59]. Hence, it is within the realm of possibility that LMTK2 might be regulating AR by regulating the activity of phosphatase. In terms of potential therapeutic target, small molecules that enhance the activity of LMTK2 can decrease AR-proliferative activity in patients with prostate cancer and more importantly with castrate resistant prostate cancer.

Concluding Remarks

The study of the pathways by which AR is regulated in the normal prostate as well as prostate cancer tissue has led to the discovery of several new pathways overlapping between the fields of endocrinology and oncology. Here, we have reviewed a few recently discovered kinase pathways, which play an important role in the development of prostate cancer and its progression to CRPC. Furthermore, we also provide a list of kinases that are known to regulate AR. Clearly, there is still a lot to understand about AR regulation through phosphorylation. Moreover, the requisite phosphatases required to reverse phosphorylation events have barely been elucidated. Upstream regulators for many kinases remain unknown and so does the full biological significance of AR phosphorylation in the context of normal and cancerous physiology of prostate epithelial cells. We do not believe that AR-kinase pathways are the only pathways leading to CRPC and, no doubt, further studies will reveal additional pathways. It is highly likely that not all the CRPC patients have dysregulation of the same pathways; hence an effective therapy of CRPC will require that therapy address each patient individually. Nonetheless, the plethora of kinases that impinge upon AR to regulate its signaling provide many potential novel therapeutic targets to treat the roughly 50% of the population that will develop some form of prostate abnormalities with age, and more specifically for those individuals who develop malignant CRPC.

Conflicting interests

The authors have declared that no competing interests exist.

Acknowledgements

This work was supported by the National Institutes of Health (1R01HL102208-01A1) and Cystic Fibrosis Foundation grants (BRADBU12XXO), awarded to Bradbury N.A.

References


46. Christoffersen J, Smeland EB, Stokke T, Taskén K, Andersson


